Launch of Potassium chloride determined
On 1st of March, EQL Pharma launches the drug Potassium chloride on the Swedish market.
"The goal of launching Potassium chloride has been the first half of 2018 and we have been working hard to launch the product as soon as possible. Launching in March is of course positive for the company, "says EQL Pharma's CEO, Christer Fåhraeus.
Potassium chloride EQL Pharma is part of EQL Pharmas long-term commitment to new strategic niche generics with little or no competition. Total sales in Sweden and Denmark are approximately SEK 140 million annually and there is currently one competitor in addition to the original.
Sales of the drug on the Danish market will be through a cooperation with a leading generic company as previously communicated. Launch on the Danish market will take place in the first half of 2018.
Potassium chloride EQL Pharma belongs to a group of medicines called minerals. Potassium chloride is given to patients with low levels of potassium in the blood. It can also be given for prevention in diuretic treatment.
For further information, please contact:
Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com
About EQL Pharma
EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets eight (8) niche generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (8) people and is listed on AktieTorget. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.